” Amendment replaces saline injections with sham injections in the control group ” MELVILLE, N.Y., April 16, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (BioRestorative, BRTX or...
” Collaboration follows recent manufacturing/clinical process enhancements that have tripled monthly trial capacity ” ” Patient enrollment expected to be completed in 2024 ” ...
- Company is not offering shares pursuant to the registration statement - MELVILLE, N.Y., April 03, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (BioRestorative, BRTX or the...
MELVILLE, N.Y., April 01, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (BioRestorative, BRTX or the Company) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based...
BioRestorative Therapies to Participate in the 36th Annual ROTH Conference
Preliminary data includes 26 and 52-week follow-up end points as part of ongoing Phase 2 trial Company to host webcasted conference call today at 8:30am EST MELVILLE, N.Y., Feb. 05,...
” Blinded data from the ongoing Phase 2 clinical trial of BRTX-100 to be described in poster presentation ” ” Company to host webcasted conference call to review data on February 5, 2024 at...
--Notice of allowance will be the fourth U.S. patent granted under Company™s ThermoStem® program targeting obesity and metabolic disorders, including type 2 diabetes-- MELVILLE, N.Y., Dec. 12, 2023 ...
MELVILLE, NY., Oct. 09, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the œCompany or œBioRetorative) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies,...